ProQR Therapeutics N.V. (PRQR): Operating Sales Margin

ProQR (PRQR) - corporate logo

ProQR Therapeutics N.V. (PRQR) is utilizing flexible management to optimize its drug portfolio, impacting the quarterly operating margin tracked by GURU.Markets analytics. The value of -234.10 determines the current status of the parameter. Strong pricing power within the Axiomer RNA editing segment and the efficient delegation of trials to external CROs support the business's fundamental stability, minimizing operational risks during the development of innovative medicines.

PRQR - ProQR Operating Profit Ratio over the range 07/04/2022 - 11/19/2026

Analytical breakdowns for ProQR Therapeutics N.V.

- share price and consensus valuation forecast:
Initial company analysis:ProQR
Finished products of ProQR

Investors in ProQR Therapeutics N.V. (PRQR) must evaluate the effectiveness of intellectual property monetization within the RNA editing sector. This indicator determines the share of operating profit in total revenue, excluding the impact of debt load and taxation. By analyzing the operating profit margin, one can assess the scalability of the Axiomer platform. Licensing payments from Eli Lilly minimize capital expenditures, directly increasing margins. Steady growth in this metric confirms the sustainability of a business model that avoids capital-intensive production.

Competitor analysis for ProQR Therapeutics N.V.

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|benitec.com - Operating Margin|DSGN - Operating Margin|RCKT: Operating Margin|FDMT (4D Molecular Therapeutics Inc) - Operating Profitability|Operating Sales Margin LXEO|Operating Profitability KRRO|Operating Margin EDIT|SLN - Operating Return on Sales|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability